Filters

Term Search
You can select from the dropdown list OR enter your own terms to refine the search.

Last Updated: 10/31/2025

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 85 publications

Deep Learning-Based Body Composition Analysis for Outcome Prediction in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Insights From the LOTIS-2 Trial.

Deep Learning-Based Body Composition Analysis for Outcome Prediction in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Insights From the LOTIS-2 Trial.

Journal: JCO clinical cancer informatics
Published: July 16, 2025

Loncastuximab tesirine in relapsed/refractory diffuse large B-cell lymphoma: drug profile and expert opinion on the prevention and management of adverse events.

Loncastuximab tesirine in relapsed/refractory diffuse large B-cell lymphoma: drug profile and expert opinion on the prevention and management of adverse events.

Journal: Leukemia & lymphoma
Published: June 30, 2025

Bispecific Antibodies and Antibody-Drug Conjugates in Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma, Focusing on Diffuse Large B-Cell Lymphoma.

Bispecific Antibodies and Antibody-Drug Conjugates in Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma, Focusing on Diffuse Large B-Cell Lymphoma.

Journal: Cancers
Published: June 29, 2025

Targeted Therapies and Immunotherapies for Diffuse Large B-Cell Lymphoma.

Targeted Therapies and Immunotherapies for Diffuse Large B-Cell Lymphoma.

Journal: Cancers
Published: June 26, 2025

Loncastuximab tesirine elicits complete responses in secondary central nervous system lymphoma.

Loncastuximab tesirine elicits complete responses in secondary central nervous system lymphoma.

Journal: British journal of haematology
Published: June 17, 2025

Real-world treatment of large B-cell lymphoma with chimeric antigen receptor T-cell therapy after loncastuximab tesirine: a plain language summary.

Real-world treatment of large B-cell lymphoma with chimeric antigen receptor T-cell therapy after loncastuximab tesirine: a plain language summary.

Journal: Future oncology (London, England)
Published: May 30, 2025

How well does loncastuximab tesirine work after chimeric antigen receptor T-cell treatment in diffuse large B-cell lymphoma? A plain language summary of a real-world evidence study.

How well does loncastuximab tesirine work after chimeric antigen receptor T-cell treatment in diffuse large B-cell lymphoma? A plain language summary of a real-world evidence study.

Journal: Future oncology (London, England)
Published: May 29, 2025

Management of Adverse Reactions to Loncastuximab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma.

Management of Adverse Reactions to Loncastuximab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma.

Journal: Hematological oncology
Published: May 28, 2025

Advanced Antibody-Drug Conjugates Design: Innovation in Linker Chemistry and Site-Specific Conjugation Technologies.

Advanced Antibody-Drug Conjugates Design: Innovation in Linker Chemistry and Site-Specific Conjugation Technologies.

Journal: Chembiochem : a European journal of chemical biology
Published: April 11, 2025

Budget impact of introducing glofitamab for treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy in the United States.

Budget impact of introducing glofitamab for treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy in the United States.

Journal: Journal of medical economics
Published: March 31, 2025

Response to Michelerio et al regarding "Antibody-drug conjugates: A review of cutaneous adverse effects".

Response to Michelerio et al regarding "Antibody-drug conjugates: A review of cutaneous adverse effects".

Journal: Journal of the American Academy of Dermatology
Published: March 22, 2025

Polatuzumab vedotin and CD79B: A study of efficacy in R-CHOP-resistant diffuse large B-cell lymphoma.

Polatuzumab vedotin and CD79B: A study of efficacy in R-CHOP-resistant diffuse large B-cell lymphoma.

Journal: British journal of haematology
Published: February 15, 2025
Showing 1-12 of 85

Last Updated: 10/31/2025